<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="guidance arose in November 2014 from information provided by the" exact="Public Health Agency" post="of Canada regarding early data indicating a mismatch of"/>
 <result pre="is needed, it can be obtained by request to the" exact="Government of Canada" post="Health Protection Branch, Special Access Program, Ottawa. (Web access"/>
 <result pre="Research: Biocryst Inc. Dr Upton D Allen: Research: Hoffmann La" exact="Roche" post="Inc. Dr H Grant Stiver: Honoraria: Hoffman La Roche"/>
 <result pre="La Roche Inc. Dr H Grant Stiver: Honoraria: Hoffman La" exact="Roche" post="Inc; Advisory Board: Hoffman La Roche Inc. Dr Gerald"/>
 <result pre="Stiver: Honoraria: Hoffman La Roche Inc; Advisory Board: Hoffman La" exact="Roche" post="Inc. Dr Gerald A Evans: Research: Biocryst Inc. Dr"/>
 <result pre="of 75 mg orally twice daily for adults (13–15). The" exact="American Academy of Pediatrics" post="recommended an oseltamivir treatment dose of 3.5 mg/kg orally"/>
 <result pre="the AAP [14] and is based on data from the" exact="National Institute of Allergy and Infectious Diseases" post="Collaborative Antiviral Study Group using the infants’ postmenstrual age"/>
</results>
